Burmester GR, Gottenberg JE, Caporali R, Winthrop KL, et al. Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years. Ann Rheum Dis 2024 May 23:ard-2024-225759. doi: 10.1136/ard-2024-225759.
PMID: 38782549